ReCode Therapeutics is gearing up for human clinical trials of its primary ciliary dyskinesia (PCD) and cystic fibrosis therapies next year.
Kevin Cummings, Biz Journals
Fri, 10/22/2021 - 8:59pm
ReCode Therapeutics is gearing up for human clinical trials of its primary ciliary dyskinesia (PCD) and cystic fibrosis therapies next year.